Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
Das JR, Fryar-Tita EB, Green S, Southerland WM, Bowen D. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow. Anticancer Res. 2007 Mar-Apr; 27(2):825-33.